Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

NCT02763384 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02763384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02763384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
December 2, 2016
Completion date
May 22, 2022
Enrollment
12 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adult t lymphoblastic lymphoma, t-acute lymphoblastic leukemia